Chk1 inhibition was also found to sensitize colorectal cancer stem cells to nortopsentin and to radiosensitize head-and-neck cancers to paclitaxel-based chemoradiotherapy [9]. This evidence concerns the gene CHEK1 and colorectal cancer.